Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.
Completed · Phase 2
Conditions studied: Relapsing Forms of Multiple Sclerosis
In brief
Primary objective is to evaluate the immune response to vaccination with tetanus diphtheria toxoids vaccine (Td) in participants with relapsing forms of Multiple Sclerosis (MS) who have been treated with Tecfidera (BG00012) versus those treated with non pegylated interferon (IFN). Secondary objective is to evaluate the immune response to vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) \[a mostly T cell-independent humoral response\] and meningococcal polysaccharide diphtheria conjugate vaccine, quadrivalent (MCV4) \[T cell-dependent neoantigen response\].
Key facts
- Study ID
- NCT02097849
- Run by
- Biogen
- People needed
- 71
- Starts
- 2015-02-28
- Expected to finish
- 2016-05-02
- Last updated by the study team
- 2017-06-02
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Gilbert, Arizona, United States
- Research Site — Thornton, Colorado, United States
- Research Site — Fort Lauderdale, Florida, United States
- Research Site — Sarasota, Florida, United States
- Research Site — Indianapolis, Indiana, United States
- Research Site — Lexington, Kentucky, United States
- Research Site — Auburn, Maine, United States
- Research Site — New York, New York, United States
- Research Site — Charlotte, North Carolina, United States
- Research Site — Akron, Ohio, United States
- Research Site — Cleveland, Ohio, United States
- Research Site — Dayton, Ohio, United States
- Research Site — Round Rock, Texas, United States
- Research Site — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.